Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database

• Published in: Annals of hematology Vol. 97; no. 11; pp. 2081 - 2088
• Main Authors: Fujioka, Isao, Takaku, Tomoiku, Iriyama, Noriyoshi, Tokuhira, Michihide, Kimura, Yuta, Sato, Eriko, Ishikawa, Maho, Nakazato, Tomonori, Sugimoto, Kei-Ji, Fujita, Hiroyuki, Asou, Norio, Kizaki, Masahiro, Hatta, Yoshihiro, Komatsu, Norio, Kawaguchi, Tatsuya
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2018; Springer Nature B.V
• Subjects: Hematology; Leukemia; Medicine; Medicine & Public Health; Oncology; Original Article; Cardiovascular disease; Japanese patients; Vascular adverse events; Chronic myeloid leukemia; Tyrosine kinase inhibitor
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-018-3412-8

This study investigated the incidence rate and features of vascular adverse events (VAEs) in Japanese patients with chronic myeloid leukemia (CML) who were treated with tyrosine kinase inhibitors (TKIs). The analysis included 369 CML patients in the chronic or accelerated phases, selected from the CML Cooperative Study Group database; 25 events in 23 (6.2%) of these patients were VAEs. At the time of VAE incidence, nine patients were on treatment with imatinib, 12 with nilotinib, three with dasatinib, and one with bosutinib. VAE incidence comprised 13 cases of ischemic heart disease (IHD), eight of cerebral infarction (CI), and four of peripheral arterial occlusive disease (PAOD). IHD incidence rate in the study population was higher than that in the age-matched general population, particularly in nilotinib-treated patients, while CI incidence rate was almost equivalent. Compared with the Suita score, the SCORE chart and the Framingham score risk assessment tools detected more patients with high or very high risk of VAEs. In conclusion, incidence of IHD requires closer monitoring in nilotinib-treated patients. More detailed investigations for determining the most useful tool to predict VAE incidence and long-term analysis of therapy-related VAE cases are needed for improving safety during TKI therapy.